Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park, Y.H.; Senkus-Konefka, E.; Im, Seock‐Ah; Pentheroudakis, George; Saji, Shigehira; Gupta, Sudeep; Iwata, Hiroji; Mastura, M.Y.; Dent, Rebecca; Lu, Yen‐Shen; Yin, Yifei; Smruti, B K; Toyama, Tatsuya; Malwinder, S.; Lee, S.C.; Tseng, Ling‐Ming; Kim, J.H.; Kim, T.-Y.; Suh, Koung Jin; Cardoso, Fátima; Yoshino, Takayuki; Jy, Douillard

doi:10.1016/j.annonc.2020.01.008

Cited by 48 publications

(34 citation statements)

References 65 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the National Comprehensive Cancer Network (NCCN) [ 23 , 24 ], Arbeitsgemeinschaft Gynakologische Onkologie (AGO) [ 25 ], National Institute for Health and Care Excellence (NICE) [ 26 ], Japanese Breast Cancer Society Clinical Practice (JBCSCP) [ 27 ] and Pan-Asian adapted ESMO Clinical Practice Guidelines [ 28 ] give no recommendations on OMBC.…”

Section: Resultsmentioning

confidence: 99%

Diagnosis, biology and epidemiology of oligometastatic breast cancer

et al. 2021

View full text Add to dashboard Cite

Does oligometastatic breast cancer (OMBC) deserve a dedicated treatment? Although some authors recommend multidisciplinary management of OMBC with a curative intent, there is no evidence proving this strategy beneficial in the absence of a randomized trial. The existing literature sheds little light on OMBC. Incidence is unknown; data available are either obsolete or biased; there is no consensus on the definition of OMBC and metastatic sites, nor on necessary imaging techniques. However, certain proposals merit consideration. Knowledge of eventual specific OMBC biological characteristics is limited to circulating tumor cell (CTC) counts. Given the data available for other cancers, studies on microRNAs (miRNAs), circulating tumor DNA (ctDNA) and genomic alterations should be developed Finally, safe and effective therapies do exist, but results of randomized trials will not be available for many years. Prospective observational cohort studies need to be implemented.

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnosis, biology and epidemiology of oligometastatic breast cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Imaging examinations (such as bilateral breast X-ray imaging, positron emission tomography–computed tomography, and ultrasound), histological findings, and especially molecular pathology are the predominant methods of breast cancer diagnosis and assessment [ 7 , 8 ]. Based on the tumor burden, optimal treatments, namely breast-conserving surgery, radiotherapy, chemotherapy, and endocrine therapy, are individually designed for breast cancer patients [ 6 ]. For TNBC patients, anthracyclines and taxanes are preferred in the initial treatment, and neoadjuvant therapy has been recognized as a standard strategy [ 9 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Other risk factors, such as early or delayed menstruation, nulliparity, hormone replacement therapy, and alcohol consumption, also contribute to the prevalence of breast cancer [5]. Clinical practice guidelines recommend that females aged 40-49 or 70-74, who are at higher risk, screen for breast cancer [6]. Imaging examinations (such as bilateral breast X-ray imaging, positron emission tomography-computed tomography, and ultrasound), histological findings, and especially molecular pathology are the predominant methods of breast cancer diagnosis and assessment [7,8].…”

mentioning

confidence: 99%

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Wei

Zeng

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: The situation faced by breast cancer patients, especially those with triple-negative breast cancer, is still grave. More effective therapeutic targets are needed to optimize the clinical management of breast cancer. Although collagen type VIII alpha 1 chain (COL8A1) has been shown to be downregulated in BRIP1-knockdown breast cancer cells, its clinical role in breast cancer remains unknown. Methods: Gene microarrays and mRNA sequencing data were downloaded and integrated into larger matrices based on various platforms. Therefore, this is a multi-centered study, which contains 5048 breast cancer patients and 1161 controls. COL8A1 mRNA expression in breast cancer was compared between molecular subtypes. In-house immunohistochemistry staining was used to evaluate the protein expression of COL8A1 in breast cancer. A diagnostic test was performed to assess its clinical value. Furthermore, based on differentially expressed genes (DEGs) and coexpressed genes (CEGs) positively related to COL8A1, functional enrichment analyses were performed to explore the biological function and potential molecular mechanisms of COL8A1 underlying breast cancer. Results: COL8A1 expression was higher in breast cancer patients than in control samples (standardized mean difference = 0.79; 95% confidence interval [CI] 0.55-1.03). Elevated expression was detected in various molecular subtypes of breast cancer. An area under a summary receiver operating characteristic curve of 0.80 (95% CI 0.76-0.83) with sensitivity of 0.77 (95% CI 0.69-0.83) and specificity of 0.70 (95% CI 0.61-0.78) showed moderate capacity of COL8A1 in distinguishing breast cancer patients from control samples. Worse overall survival was found in the higher than in the lower COL8A1 expression groups. Intersected DEGs and CEGs positively related to COL8A1 were significantly clustered in the proteoglycans in cancer and ECM-receptor interaction pathways. Conclusions: Elevated COL8A1 may promote the migration of breast cancer by mediating the ECM-receptor interaction and synergistically interplaying with DEGs and its positively related CEGs independently of molecular subtypes. Several genes clustered in the proteoglycans in cancer pathway are potential targets for developing effective agents for triple-negative breast cancer.

show abstract

“…On the other hand, its breast cancer death comprised about half of worldwide mortality, reaching more than 300,000 deaths. 2 The World Health Organization declared the Coronavirus disease 2019 (COVID-19) as a public health emergency of international concern. The newly discovered disease is a challenge for health care professionals.…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer Management during Coronavirus Disease 2019 Pandemic: A Literature Review

Kurniawan

Halim

Giselvania

et al. 2021

ASJO

View full text Add to dashboard Cite

Introduction Breast cancer is the most prevalent cancer found in women. The World Health Organization declared the coronavirus disease 2019 (COVID-19) as a public health emergency of international concern. Delaying treatment was associated with mortality. The aim is to evaluate breast cancer management during the pandemic. Methods We searched articles evaluating the management of breast cancer in the midst of COVID-19 outbreak, by searching in PubMed, PubMed Central, and Oncology Society related websites. We only included articles discussing adult breast cancer management in COVID-19 era. The two reviewers screened the titles and abstracts. Results Around 124 articles were found through the searching process. Eight observational trials, two review articles, six guidelines or recommendations, and one letter to the editor were included in final review. It was concluded that breast cancer posed a risk to contract COVID-19. Newly suspected breast cancer could be deferred for screening or diagnosis, except for special breast cancer cases with bleeding, invasive, and complicated tumors. The benefit of radiotherapy option in every case should be carefully weighed against the risk of infection. Oral chemotherapy and hormonal therapy drugs were preferred to be given than intravenous chemotherapy. The scheduled chemotherapy could be adjusted to reduce hospital visit. Each breast cancer patient is different, so they should be discussed in multidisciplinary team consisting of surgical, radiation, and medical oncologists, pathologist, radiologist, palliative care people, nurses, nutritionist, and others related to the field. Conclusion The International Oncology Society has released recommendations for breast cancer during COVID-19 pandemic but there is still questionable-quality evidence.

show abstract

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Cited by 48 publications

References 65 publications

Diagnosis, biology and epidemiology of oligometastatic breast cancer

Diagnosis, biology and epidemiology of oligometastatic breast cancer

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Breast Cancer Management during Coronavirus Disease 2019 Pandemic: A Literature Review

Contact Info

Product

Resources

About